Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma

Clinical Cancer Research

Volumn 19, Issue 23, 2013, Pages 6484-6494

  Zheng, Ying ^a   McFarland, Braden C ^a   Drygin, Denis ^d   Yu, Hao ^a   Bellis, Susan L ^a   Kim, Hyunsoo ^b   Bredel, Markus ^c   Benveniste, Etty N ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c The University of Alabama at Birmingham   (United States)

^d Cylene Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; BETA1 INTEGRIN; CASEIN KINASE II; CX 4945; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; SMALL INTERFERING RNA; STAT PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER SURVIVAL; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; CSNK2A1 GENE; DISEASE ASSOCIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENE; GENE DOSAGE; GENE EXPRESSION; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CASEIN KINASE II; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; NAPHTHYRIDINES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890283008     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0265     Document Type: Article

References (49)

1. Verhaak R G W, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
2. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
3. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012;26:756-84.
4. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010;463:318-25.
5. Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, et al. NFKBIA deletion in Glioblastomas. N Engl J Med 2011;364:627-37.
6. Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, et al. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol 2012;14:1136-45.
7. Atkinson GP, Nozell SE, Benveniste ET. NF-kappaB and STAT3 signaling in glioma: targets for future therapies. Expert Rev Neurother 2010;10:575-86.
8. Brantley EC, Nabors LB, Gillespie GY, Choi YH, Palmer CA, Harrison K, et al. Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res 2008;14:4694-704.
9. Lo HW, Cao X, Zhu H, Ali-Osman F. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in highgrade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res 2008;14:6042-54.
10. McFarland BC, Ma JY, Langford CP, Gillespie GY, Yu H, Zheng Y, et al. Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther 2011;10:2384-93.
11. Raychaudhuri B, Han Y, Lu T, Vogelbaum MA. Aberrant constitutive activation of nuclear factor kB in glioblastoma multiforme drives invasive phenotype. J Neuro Oncol 2007;85:39-47.
12. Zhao X, Laver T, Hong S, Twitty G, De Vos A, De Vos M, et al. An NF-kB p65-cIAP2 link is necessary for mediating resistance to TNF-a induced cell death in gliomas. J Neuro Oncol 2011;102:367-81.
13. Duncan JS, Litchfield DW. Too much of a good thing: The role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta 2008;1784:33-47.
14. Ruzzene M, Pinna LA. Addiction to protein kinase CK2: A common denominator of diverse cancer cells?Biochim Biophys Acta 2010;1804:499-504.
15. Zheng Y, Qin H, Stuart F, Deng L, Litchfield DW, Terfferi A, et al. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. BLOOD 2011;118:156-66.
16. Drygin D, Ho CB, Omori M, Bliesath J, Proffitt C, Rice R, et al. Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer. Biochem Biophysical Res Commun 2011;415:163-7.
17. Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 2011;70:10288-98.
18. Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, et al. Discovery and SAR of 5-(3-chlorophenylamino) benzo[c][2, 6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J Med Chem 2011;54:635-54.
19. Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, et al. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol Cell Biochem 2011;356:37-43.
20. Marschke RF, Borad MJ, McFarland RW, Alvarez RH, Lim JK, Padgett CS, et al. Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2. ASCO Meeting Abstracts 2011;29:3087.
21. Ladha J, Donakonda S, Agrawal S, Thota B, Srividya MR, Sridevi S, et al. Glioblastoma-specific protein interaction network identifies PP1A and CSK21 as connecting molecules between cell cycle-associated genes. Cancer Res 2010;70:6437-47.
22. Kaminska B, Ellert-Miklaszewska A, Oberbek A, Wisniewski P, Kaza B, Makowska M, et al. Efficacy and mechanism of anti-tumor action of new potential CK2 inhibitors toward glioblastoma cells. Int J Oncol 2009;35:1091-100.
23. Prudent R, Moucadel V, Nguyen CH, Barette C, Schmidt F, Florent JC, et al. Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2. Cancer Res 2010;70:9865-74.
24. Moucadel V, Prudent R, Sautel CF, Teillet F, Barette C, Lafanechere L, et al. Antitumoral activity of allosteric inhibitors of protein kinase CK2. Oncotarget 2011;2:997-1010.
25. Olsen BB, Issinger OG, Guerra B. Regulation of DNA-dependent protein kinase by protein kinase CK2 in human glioblastoma cells. Oncogene 2010;29:6016-26.
26. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011;12:R41.
27. Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, et al. Targeting Interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 2009;27:2393-404.
28. Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J, et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 2011;19:498-511.
29. Cao Y, Lathia JD, Eyler CE, Wu Q, Li Z, Wang H, et al. Erythropoietin receptor signaling through STAT3 is required for glioma stem cell maintenance. Genes Cancer 2010;1:50-61.
30. Puram SV, Yeung CM, Jahani-Asl A, Lin C, De La Iglesia N, Konopka G, et al. STAT3-iNOS signaling mediates EGFRvIII-induced glial proliferation and transformation. J Neurosci 2012;32:7806-18.
31. Van Wagoner N, Oh J-W, Repovic P, Benveniste EN. IL-6 production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor. J Neurosci 1999;19:5236-44.
32. Lou DY, Dominguez I, Toselli P, Landesman-Bollag E, O'Brien C, Seldin DC. The alpha catalytic subunit of protein kinase CK2is required for mouse embryonic development. Mol Cell Biol 2008;28:131-9.
33. Seldin DC, Landesman-Bollag E, Farago M, Currier N, Lou D, Dominguez I. CK2 as a positive regulator of Wnt signalling and tumourigenesis. Mol Cell Biochem 2005;274:63-7.
34. Repovic P, Fears CY, Gladson CL, Benveniste EN. Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells. Oncogene 2003;22:8117-24.
35. Joughin BA, Naegle KM, Huang PH, Yaffe MB, Lauffenburger DA, White FM. An integrated comparative phosphoproteomic and bioinformatic approach reveals a novel class of MPM-2 motifs upregulated in EGFRvIII-expressing glioblastoma cells. Mol Biosyst 2009;5:59-67.
36. Gadji M, Crous AM, Fortin D, Krcek J, Torchia M, Mai S, et al. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts. Eur J Pharmacol 2009;625:23-30.
37. Quesnelle KM, Boehm AL, Grandis JR. STAT-mediated EGFR signaling in cancer. J Cell Biochem 2007;102:311-9.
38. Wang D, Westerheide SD, Hanson JL, Baldwin AS Jr. Tumor necrosis factor a-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem 2000;275:32592-7.
39. Network, T. C. G. A. R. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
40. Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. J Biol Chem 2001;276:993-8.
41. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F, et al. Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 2005;12:668-77.
42. Canton DA, Litchfield DW. The shape of things to come: an emerging role for protein kinase CK2 in the regulation of cell morphology and the cytoskeleton. Cell Signal 2006;18:267-75.
43. Kramerov AA, Golub AG, Bdzhola VG, Yarmoluk SM, Ahmed K, Bretner M, et al. Treatment of cultured human astrocytes and vascular endothelial cells with protein kinase CK2 inhibitors induces early changes in cell shape and cytoskeleton. Mol Cell Biochem 2011;349:125-37.
44. Garcia-Pardo A, Wayner EA, Carter WG, Ferreira OC Jr. Human B lymphocytes define an alternative mechanism of adhesion to fibronectin. The interaction of the alpha 4 beta 1 integrin with the LHGPEILDVPST sequence of the type III connecting segment is sufficient to promote cell attachment. J Immunol 1990;144:3361-6.
45. Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, et al. A network model of a cooperative genetic landscape in brain tumors. JAMA 2009;302:261-75.
46. Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G, et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 2006;108:1698-707.
47. Kohsaka S, Wang L, Yachi K, Mahabir R, Narita T, Itoh T, et al. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol Cancer Ther 2012;11:1289-99.
48. Miyata Y. Protein kinase CK2 in health and disease: CK2: the kinase controlling the Hsp90 chaperone machinery. Cell Mol Life Sci 2009;66:1840-9.
49. Edwards LA, Woolard K, Son MJ, Li A, Lee J, Ene C, et al. Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J Natl Cancer Inst 2011;103:1162-78.